Skip to main content
. 2019 Dec 5;2019(12):CD011260. doi: 10.1002/14651858.CD011260.pub2

Comparison 2. IPV‐OPV versus IPV.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Persons with P1 Protective humoral response 10 2858 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.99, 1.01]
1.1 Sequential IOO 4 572 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.98, 1.02]
1.2 Sequential IIO(O) 8 1767 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.99, 1.01]
1.3 Sequential IbOI 1 519 Risk Ratio (M‐H, Random, 95% CI) 1.05 [1.00, 1.10]
2 Persons with P2 Protective humoral response 10 2907 Risk Ratio (M‐H, Random, 95% CI) 0.97 [0.95, 1.00]
2.1 Sequential IbObO 2 382 Risk Ratio (M‐H, Random, 95% CI) 0.76 [0.64, 0.91]
2.2 Sequential IOO 3 227 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.96, 1.04]
2.3 Sequential IIO(O) 8 1779 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.99, 1.01]
2.4 Sequential IbOI 1 519 Risk Ratio (M‐H, Random, 95% CI) 0.95 [0.88, 1.02]
3 Persons with P3 Protective humoral response 9 2620 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.97, 1.01]
3.1 Sequential IOO 4 570 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.96, 1.02]
3.2 Sequential IIO(O) 7 1531 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.96, 1.01]
3.3 Sequential IbOI 1 519 Risk Ratio (M‐H, Random, 95% CI) 1.01 [0.96, 1.05]
4 Mean titres of P1 neutralising antibody 2   Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Sequential IbObO 1 127 Mean Difference (IV, Random, 95% CI) 1520.59 [1084.80, 1956.38]
4.2 Sequential IOO 1 127 Mean Difference (IV, Random, 95% CI) 799.47 [530.82, 1068.12]
4.3 Sequential IIbO 1 127 Mean Difference (IV, Random, 95% CI) 866.53 [478.83, 1254.23]
4.4 Sequential IIO 2 363 Mean Difference (IV, Random, 95% CI) 767.90 [337.75, 1198.06]
5 Mean titres of P2 neutralising antibody 2   Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Sequential IbObO 1 127 Mean Difference (IV, Random, 95% CI) ‐125.93 [‐174.77, ‐77.09]
5.2 Sequential IOO 1 127 Mean Difference (IV, Random, 95% CI) 142.25 [57.65, 226.85]
5.3 Sequential IIbO 1 127 Mean Difference (IV, Random, 95% CI) ‐83.45 [‐133.40, ‐33.50]
5.4 Sequential IIO 2 362 Mean Difference (IV, Random, 95% CI) 2224.48 [‐1145.70, 5594.67]
6 Mean titres of P3 neutralising antibody 2   Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Sequential IbObO 1 127 Mean Difference (IV, Random, 95% CI) 327.62 [134.82, 520.42]
6.2 Sequential IOO 1 127 Mean Difference (IV, Random, 95% CI) 110.39 [‐77.98, 298.76]
6.3 Sequential IIbO 1 127 Mean Difference (IV, Random, 95% CI) 698.37 [301.06, 1095.68]
6.4 Sequential IIO 2 360 Mean Difference (IV, Random, 95% CI) 184.52 [‐211.93, 580.97]
7 Long term mean titres of P1 neutralising antibody 1   Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 Sequential IOO 1 37 Mean Difference (IV, Random, 95% CI) ‐0.20 [‐0.73, 0.33]
7.2 Sequential IOO+O 1 37 Mean Difference (IV, Random, 95% CI) ‐0.30 [‐0.83, 0.23]
7.3 Sequential IIO 1 40 Mean Difference (IV, Random, 95% CI) 0.40 [‐0.04, 0.84]
7.4 Sequential IIO+O 1 40 Mean Difference (IV, Random, 95% CI) 0.90 [0.40, 1.40]
8 Long term mean titres of P2 neutralising antibody 1   Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 Sequential IOO 1 37 Mean Difference (IV, Random, 95% CI) 0.20 [‐0.06, 0.46]
8.2 Sequential IOO+O 1 37 Mean Difference (IV, Random, 95% CI) ‐0.60 [‐0.96, ‐0.24]
8.3 Sequential IIO 1 40 Mean Difference (IV, Random, 95% CI) 0.10 [‐0.19, 0.39]
8.4 Sequential IIO+O 1 40 Mean Difference (IV, Random, 95% CI) ‐0.40 [‐0.78, ‐0.02]
9 Long term mean titres of P3 neutralising antibody 1   Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 Sequential IOO 1 37 Mean Difference (IV, Random, 95% CI) ‐0.60 [‐1.22, 0.02]
9.2 Sequential IOO+O 1 37 Mean Difference (IV, Random, 95% CI) ‐0.30 [‐0.76, 0.16]
9.3 Sequential IIO 1 40 Mean Difference (IV, Random, 95% CI) 0.30 [‐0.04, 0.64]
9.4 Sequential IIO+O 1 40 Mean Difference (IV, Random, 95% CI) ‐0.10 [‐0.46, 0.26]
10 Persons with polio faecal excretion after OPV challenge 3   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
10.1 Persons with P1 faecal excretion (ibOI) 1 519 Risk Ratio (M‐H, Random, 95% CI) 0.27 [0.19, 0.39]
10.2 Persons with P1 faecal excretion (IIO/IIOO) 1 303 Risk Ratio (M‐H, Random, 95% CI) 1.04 [0.59, 1.84]
10.3 Persons with P2 faecal excretion (ibOI/IIbO) 2 1048 Risk Ratio (M‐H, Random, 95% CI) 0.85 [0.68, 1.06]
10.4 Persons with P2 faecal excretion (IIO/IIOO) 1 303 Risk Ratio (M‐H, Random, 95% CI) 0.16 [0.09, 0.28]
10.5 Persons with P3 faecal excretion (ibOI) 1 519 Risk Ratio (M‐H, Random, 95% CI) 0.37 [0.26, 0.54]
10.6 Persons with P3 faecal excretion (IIO/IIOO) 1 303 Risk Ratio (M‐H, Random, 95% CI) 0.40 [0.32, 0.50]
11 Serious adverse events (≥1 symptom related to study drug or not) 2 1063 Risk Ratio (M‐H, Random, 95% CI) 0.92 [0.60, 1.43]